Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a phase II study that will assess if Durvalumab (MEDI4736) used as induction
chemo-immunotherapy followed by concurrent chemo-immuno-radiotherapy and consolidation
immunotherapy may improve oncologic outcomes compared with standard of care chemoradiation
followed by durvalumab (as in the PACIFIC trial) with a reasonable safety profile.